In addition, the activation of the STING/IFN-I pathway was also indicated to elevate CCR2 expression, and suppressive inflammation in colon tumors through recruiting MDSCs, CCR2 blockage-mitigated MDSC infiltration, and immunosuppression initiated by STING activation enhanced oncotherapy (Liang et al., 2017). Here, CCR2 is linked to colonic neoplasm.